In what ways could AI‑driven detection of coronary artery calcification in routine mammograms transform preventive cardiology, health‑care cost structures, and regulatory frameworks?
Cardiovascular disease remains the leading cause of death among women globally, yet traditional risk assessment tools consistently underperform in female populations, leaving many women undiagnosed until experiencing acute cardiac events Breast Arterial Calcification as a Cardiovascular Risk Factor: Time to “Bust” It Out - PMC nih . The convergence of artificial intelligence capabilities with existing mammography infrastructure presents an unprecedented opportunity to fundamentally reshape how cardiovascular risk is identified, managed, and financed. With approximately 27 million American women projected to undergo mammography in 2025, AI-driven detection of breast arterial calcification (BAC) could transform a routine cancer screening examination into a dual-purpose cardiovascular risk assessment platform A Review of Artificial Intelligence Models for Detecting Breast Arterial Calcification on Mammograms and Their Clinical Implications - PMC nih .
The scientific foundation linking breast arterial calcification to cardiovascular outcomes has matured considerably through recent large-scale investigations. A landmark study published in the European Heart Journal analyzed 123,762 women who participated in breast screening without known cardiovascular disease, using AI to quantify calcium deposits in breast tissueAI can predict risk of serious heart disease from mammogramsescardio . The findings demonstrated a clear dose-response relationship: women with mild calcification faced approximately 30% higher risk of serious cardiovascular disease compared to those without calcification, while moderate calcification elevated risk by more than 70%, and severe calcification increased risk two to three times higherAI can predict risk of serious heart disease from mammogramsescardio +1.
A comprehensive meta-analysis encompassing 45 studies and 68,584 women established BAC prevalence at 17.1% and confirmed robust associations with multiple cardiovascular endpointsA Systematic Review and Meta-Analysis of Breast Arterial Calcification and Its Association With Cardiovascular Disease and All-Cause Mortality.nih . Among cohort studies, BAC demonstrated association with incident stroke (risk ratio 2.05), heart failure (risk ratio 2.14), cardiac death (risk ratio 2.94), atherosclerotic cardiovascular disease composite outcomes (risk ratio 1.58), and all-cause mortality (risk ratio 2.04)A Systematic Review and Meta-Analysis of Breast Arterial Calcification and Its Association With Cardiovascular Disease and All-Cause Mortality.nih . A separate systematic review and meta-analysis of 10 cohort studies including 52,413 women confirmed that BAC presence conferred more than twofold increased stroke risk (risk ratio 2.09), persisting after adjustment for age, diabetes, hyperlipidemia, and menopausal statusBreast arterial calcifications on mammography and risk of stroke: a systematic review and meta-analysis.nih .
Research from Penn State analyzing 10,348 women with sequential mammograms demonstrated that vascular calcification was present in 19.4% at baseline, with those showing more severe calcium accumulation facing up to two times higher risk for serious cardiovascular eventsCalcium in breast arteries predicts future cardiovascular disease - Penn State Health Newspennstatehealthnews . Crucially, the study revealed that calcification progression—even appearing within as little as one year—carried additional prognostic significance. Women initially without BAC who developed calcification on follow-up mammograms faced 41% higher risk for adverse cardiovascular events, while progression from mild to higher categories conferred 59% elevated risk, and moderate-to-severe progression increased risk by 93%Calcium in breast arteries predicts future cardiovascular disease - Penn State Health Newspennstatehealthnews .
The predictive value extends meaningfully to younger women traditionally considered low-risk. Research published in JACC: Advances found BAC "especially predictive" in women ages 40 to 59How a mammogram may help identify heart diseasenbcnews . A study examining correlation between BAC detected on digital mammography and coronary artery calcification scores found that approximately two-fifths of younger women demonstrated BAC, with nearly 50% showing evidence of coronary artery calcium—suggesting approximately 70% diagnostic accuracy, with greater specificity in younger women and greater sensitivity in older womenCan Mammograms Also Screen for Calcified Arteries?youtube .
The potential transformation in preventive cardiology stems directly from persistent disparities in cardiovascular care for women. Women are 2.5 times less likely than men to be referred to a cardiologist after initial presentation with chest pain in ambulatory settings, particularly when evaluated by male physiciansThe state of US women’s heart health: A path to improved health and financial outcomesmckinsey . Women continue experiencing worse outcomes after acute coronary syndrome, receiving less frequent coronary revascularization and essential treatments at admission or discharge even when adjusted for demographics and patient characteristicsThe state of US women’s heart health: A path to improved health and financial outcomesmckinsey .
Traditional cardiovascular risk assessment tools underperform for women partly because they fail to incorporate female-specific risk factors and women have been underrepresented in the research studies underlying these modelsClassification and Reporting of Breast Arterial Calcifications: Current State and Ongoing Challenges.nih . Current risk prediction models demonstrate accuracy of only 56% to 63%—marginally better than chance—while AI-based models analyzing mammographic features achieve approximately 80% accuracyIntroduction to AI Applications in Breast Imagingyoutube . BAC may appear earlier than other traditional cardiovascular risk factors, making it a potentially valuable early biomarker, with up to 10% of women showing detectable BAC by age 40 Breast Arterial Calcification as a Cardiovascular Risk Factor: Time to “Bust” It Out - PMC nih .
The mammography-cardiovascular screening integration represents a paradigm shift toward opportunistic screening—leveraging existing clinical encounters to extract additional health information without incremental patient burden. Professor Lori Daniels of UC San Diego noted in an accompanying editorial that while two-thirds of women aged 50-69 in the European Union and nearly 70% of American women over 45 are current with mammography screening, fewer than 40% of women report knowing their cholesterol levelsAI can predict risk of serious heart disease from mammogramsescardio . BAC "has the potential to reframe this mismatch, leveraging a widely adopted cancer-screening platform to identify cardiovascular risk in women who may not otherwise engage with prevention"AI can predict risk of serious heart disease from mammogramsescardio .
The scale of potential impact is substantial. With approximately 37 million mammograms performed annually in the United States, even conservative 10% BAC prevalence estimates suggest 3 to 4 million women annually could be identified with breast arterial calcificationCan Mammograms Also Screen for Calcified Arteries?youtube . If 50% of those individuals harbor subclinical atherosclerosis, this represents approximately 2 million young women annually whose elevated cardiovascular risk could be identified through existing screening infrastructureCan Mammograms Also Screen for Calcified Arteries?youtube .
When BAC is identified, proposed clinical pathways involve cardiovascular risk assessment including lipid panels, glucose screening, coronary artery calcium scoring via chest CT, and blood pressure monitoring, alongside lifestyle interventions addressing diet, exercise, and smoking cessationHeart Health Referrals to My Heart Spark P.C.youtube . A prospective study of 494 women found that when notified of BAC presence, 57.1% of survey respondents reported discussing results with a primary care physician or cardiologist within three monthsPatient Notification About Breast Arterial Calcification on Mammography: Empowering Women With Information About Cardiovascular Risk.nih . Importantly, 81% found the BAC information helpful and 76.2% believed all women should be informed about BAC after mammographyPatient Notification About Breast Arterial Calcification on Mammography: Empowering Women With Information About Cardiovascular Risk.nih .
The Lynn Women's Health & Wellness Institute at Boca Raton Regional Hospital has implemented proactive BAC notification, providing patients with educational materials stating that "the presence of calcified arteries in your breast is a noncancerous, incidental finding, but is an indication that you may be at increased risk for cardiovascular disease"Lynn Women's Institute is Setting the Standard for Detecting Risk of Heart Disease in Mammograms | Baptist Health South Floridabaptisthealth . Patient navigators assist with referrals to cardiovascular specialists for preventive evaluation including coronary artery calcium scanningLynn Women's Institute is Setting the Standard for Detecting Risk of Heart Disease in Mammograms | Baptist Health South Floridabaptisthealth .
CureMetrix received FDA 510(k) clearance for cmAngio, the first product specifically cleared for BAC detection in mammograms CureMetrix Receives FDA Clearance for cmAngio®, First-Of-Its-Kind Solution For Detecting Breast Arterial Calcification einpresswire . The software analyzes both full-field digital mammography (FFDM) and digital breast tomosynthesis (DBT) screening mammograms to detect, localize, and mark breast arterial calcifications[PDF] October 5, 2023 CureMetrix, Inc. Rekha Anand Sr. Director ...fda . The cleared indication specifies that cmAngio "is intended to process screening mammograms to aid a qualified interpreting physician in the current manual process of identifying Breast Arterial Calcification" and works across all breast density levels with adjustable operating points to align sensitivity and specificity with clinical protocols CureMetrix Receives FDA Clearance for cmAngio®, First-Of-Its-Kind Solution For Detecting Breast Arterial Calcification einpresswire +1.
In April 2025, CureMetrix expanded FDA clearance for cmAngio to include GE Healthcare mammography platforms, building on initial clearance for Hologic systemsCureMetrix Mammogram Software Expands FDA Clearance, Validated on GE, Hologic Platforms | Imaging Technology Newsitnonline . The company received an additional 510(k) clearance (K250754) with decision date April 10, 2025K250754 - 510(k) Premarket Notification - FDAfda +1.
A validation study of 502 women comparing AI-derived BAC scores to manual assessment demonstrated very strong correlation (r = 0.83)Evaluation of a deep learning-based software to automatically detect and quantify breast arterial calcifications on digital mammogram.nih . For detecting marked coronary artery calcification, the AI system achieved 32.7% sensitivity, 96.1% specificity, 71.2% positive predictive value, 83.1% negative predictive value, and 81.9% accuracyEvaluation of a deep learning-based software to automatically detect and quantify breast arterial calcifications on digital mammogram.nih . Machine learning models have demonstrated specificity of 96.7% in BAC detection, potentially enabling accurate identification of nearly 2.6 million true positive cases annually given the projected mammography volume A Review of Artificial Intelligence Models for Detecting Breast Arterial Calcification on Mammograms and Their Clinical Implications - PMC nih .
Research using a semi-supervised deep learning model for automated BAC severity grading achieved a Jaccard similarity coefficient of 0.614, accuracy of 0.991, F1-score of 0.756, and agreement with consensus radiologists reaching weighted kappa of 0.90Semi-Supervised Deep Learning-Based Model for Segmentation of Breast Arterial Calcification on Screening Mammograms.nih . For clinically significant Grade 3 BAC, the model achieved AUC of 0.87, sensitivity of 0.80, and specificity of 0.93Semi-Supervised Deep Learning-Based Model for Segmentation of Breast Arterial Calcification on Screening Mammograms.nih .
DeepHealth announced Breast Suite in December 2025, an FDA-cleared end-to-end platform that includes breast cancer detection, risk assessment, density assessment, and—in development—breast arterial calcification assessment, with regulatory submission planned prior to end of 2025DeepHealth Launches Breast Suite, Elevating Breast Cancer Detection, Risk Stratification and Workflowglobenewswire +1. iCAD's ProFound Heart Health solution for BAC detection remained under FDA review as of late 2024, available for investigational use onlyicad20231231_10k.htm - SEC.govsec +1.
The FDA has developed substantial precedent for AI-enabled cardiovascular imaging tools through both 510(k) and De Novo pathways. An analysis of FDA-cleared cardiovascular AI devices found that 200 devices (95.7%) received 510(k) clearance while 9 (4.3%) were approved via De Novo Analysis of FDA-Approved Artificial Intelligence and Machine Learning-Enabled Cardiovascular Devices - PMC nih . The number of approvals increased sharply since the mid-2010s, with 85% of cardiovascular AI devices approved in the last 6 years Analysis of FDA-Approved Artificial Intelligence and Machine Learning-Enabled Cardiovascular Devices - PMC nih . Most common applications included electrocardiography-based arrhythmia detection (21.1%), echocardiography (16.7%), coronary artery disease detection and evaluation (16.7%), and hemodynamics monitoring (15.8%) Analysis of FDA-Approved Artificial Intelligence and Machine Learning-Enabled Cardiovascular Devices - PMC nih .
HeartLung Corp received FDA 510(k) clearance (K252029) in January 2026 for AI-CVD, described as the most comprehensive FDA-cleared opportunistic screening platform for CT imaging, enabling automated extraction of cardiovascular measurements from existing chest and abdominal CT scans without additional imaging, radiation, or workflow disruptionFDA Clears HeartLung's Imaging Platform | DAIC - Diagnostic and Interventional Cardiologydicardiology . GE Healthcare's Allia Moveo platform received FDA 510(k) clearance and CE Mark in February 2026 as a cardiovascular imaging software platform designed to aid in incidental findings and cardiovascular assessmentsIncidental Findings in Cardiac CT Rarely Significant | DAICdicardiology .
For novel devices without clear predicates, the De Novo pathway offers an alternative route. The key differences from 510(k) include: (1) identification of alternate practices and procedures if the device is not used; (2) a classification section justifying proposed Class I or II classification and efforts to identify existing product classifications; (3) a benefit-risk analysis quantifying benefits and risks with supporting clinical data; and (4) special controls identification matching risks to health with mitigations and supporting evidenceWhat is the difference between a 510k and De Novo?youtube .
The FDA granted De Novo classification (DEN240047) in September 2024 for Clairity's Allix5 software, classified as a "radiological software device to predict future breast cancer risk" that generates 5-year risk predictions based on bilateral screening mammograms[PDF] May 30, 2025 Clairity, Inc. Kris Zeschin Acting Head of Operations ...fda . This establishes regulatory precedent for AI-based risk prediction software analyzing mammography images, though the specific BAC-cardiovascular risk prediction pathway remains undefined.
The FDA issued guidance in December 2024 setting forth marketing submission recommendations for AI-enabled devices "to promote the development of safe and effective AI-enabled devices"[PDF] Liability Risk For AI In Medical Devices Demands Greater Carecrowell . By mid-2025, FDA had added 115 radiology AI algorithms to its approved list, bringing the total to approximately 873—making medical imaging the single largest AI target among medical specialtiesAI in Radiology: 2025 Trends, FDA Approvals & Adoption | IntuitionLabsintuitionlabs .
The Centers for Medicare & Medicaid Services explicitly excludes asymptomatic screening from coverage for AI-based quantitative coronary plaque analysis. The Local Coverage Determination states that AI-QCT/AI-CPA "is NOT considered reasonable or necessary" for "screening, i.e., in the absence of signs, symptoms, or disease"LCD - Artificial Intelligence Enabled CT Based Quantitative Coronary Topography (AI-QCT )/Coronary Plaque Analysis (AI-CPA) (L39881)cms . Coverage requires diagnostic indications including patients with acute or stable chest pain, no known CAD, eligible for coronary CT angiography, and intermediate risk classificationLCD - Artificial Intelligence Enabled CT Based Quantitative Coronary Topography (AI-QCT )/Coronary Plaque Analysis (AI-CPA) (L39881)cms .
However, the private payer landscape is evolving. A new permanent Category I CPT code 75577 for AI-enabled coronary plaque analysis took effect January 1, 2026, with major payers including Aetna, UnitedHealthcare, Cigna, and Humana now covering AI-enabled coronary plaque analysis Expanded Insurance Coverage Validates Circle’s AI Approach to Coronary Plaque Evaluation circlecvi . Medicare has set a national payment rate of just over $1,000 for AI plaque analysis from vendors including Heartflow, Cleerly, Elucid, and CaristoMedicare to cover $1,000 AI heart scans. Will cost match benefits? | STATstatnews .
For mammography-based BAC detection specifically, no dedicated CPT code currently exists. Stand-alone imaging centers charge patients approximately $120 out-of-pocket for AI-based BAC analysis, which insurance typically does not coverShould I Pay Extra for AI to Read My Mammogram?cuanschutz . The ProScan Mammo with Heart service explicitly notes that "like many new healthcare products, Mammo with Heart is not currently covered by insurance" though HSA/FSA accounts may be usedWomen's Services | Mammogram & Breast Health | ProScan Imagingproscan .
The economic argument for mammography-integrated cardiovascular screening rests on leveraging existing infrastructure. Coronary calcium scans typically range from $49 to $400 depending on facility and technology, with most charging between $100 and $150Heart Scan Cost: What You Need to Know Before You Schedule - Craft Body Scancraftbodyscan . By comparison, cancer screening via colonoscopy and mammography costs exceed $3,000, while coronary artery calcium testing costs less than $200Coronary artery calcium testing: A call for universal coverage.nih .
The value proposition centers on avoiding incremental costs: BAC detection requires no additional radiation exposure, no additional patient time, and no separate imaging appointment. As one researcher noted, cmAngio "shifts a screening mammogram into a two-for-one exam with no additional radiation for the patient and no new procedures for the radiologist" CureMetrix Receives FDA Clearance for cmAngio®, First-Of-Its-Kind Solution For Detecting Breast Arterial Calcification einpresswire .
The downstream cost cascade following incidental cardiovascular findings requires careful consideration. A study analyzing 1,132 CT scans found 23% yielded positive incidental findings, with 181 cardiac findings identified but only 35% of patients referred to cardiology specialistsPotential Financial Impact of Incidental Cardiac Pathology Detected During Lung Cancer Screening.nih . Total Medicare billable amounts for cardiac referrals and interventions reached $284,379, representing 35% of potential billable amounts of $804,260, with percutaneous coronary intervention representing the highest billable amount at $18,568Potential Financial Impact of Incidental Cardiac Pathology Detected During Lung Cancer Screening.nih .
Research from Ontario comparing noninvasive cardiac diagnostic testing strategies found that receipt of any noninvasive test was associated with approximately 12% reduction in downstream 1-year costs compared to no testingComparing Costs of Noninvasive Cardiac Diagnostic Tests-a Population-Based Study - PubMednih . However, different modalities showed varying cost profiles: graded exercise stress testing and stress echocardiography were associated with lower downstream costs, while coronary CT angiography and myocardial perfusion imaging were associated with higher downstream costsComparing Costs of Noninvasive Cardiac Diagnostic Tests-a Population-Based Study - PubMednih .
The cost-effectiveness of AI-based cardiovascular screening has been evaluated in analogous contexts. A pragmatic randomized controlled trial of AI-integrated ECG screening for low ejection fraction found an incremental cost-effectiveness ratio of $27,858 per quality-adjusted life year gained, remaining cost-effective across sensitivity analyses and particularly favorable in outpatient settings at $1,651/QALYCost-Effectiveness of Artificial Intelligence-Enabled Electrocardiograms for Early Detection of Low Ejection Fraction: A Secondary Analysis of the Electrocardiogram Artificial Intelligence-Guided Screening for Low Ejection Fraction Trial - PubMednih .
Professional society guidelines on BAC reporting and management have not yet been established, and assessment and quantification methods remain non-standardizedBreast Arterial Calcifications on Mammography: A Review of the Literature - PubMednih . The BI-RADS 5th edition currently describes BAC reporting as optional, while the Canadian Society of Breast Imaging recommends BAC reporting and gradingMammography to Do Double Duty - RSNA 2025 Daily Bulletinrsna . Neither the Society of Breast Imaging nor the European Society of Breast Imaging have issued formal position statementsMammography to Do Double Duty - RSNA 2025 Daily Bulletinrsna .
A Society of Breast Imaging survey found that while 85% of breast imaging radiologists were aware of the association between BAC and cardiovascular disease, only 15% routinely included BAC data in mammogram reports Breast Arterial Calcification as a Cardiovascular Risk Factor: Time to “Bust” It Out - PMC nih . A European Society of Breast Imaging survey showed over 80% of respondents were aware of the BAC-cardiovascular association and over 60% declared including BAC in reports when present, even though standard report templates do not specifically prompt for this informationBreast arterial calcifications as a biomarker of cardiovascular ...nih .
The 2019 ACC/AHA Guideline on Primary Prevention of Cardiovascular Disease incorporated risk-enhancing factors that may particularly advantage women, including pregnancy-associated conditions (preeclampsia, preterm delivery), chronic inflammatory diseases, and premature menopause Female‐friendly focus: 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease - PMC nih . For adults at borderline or intermediate 10-year ASCVD risk, guidelines support using coronary artery calcium scoring to guide clinician-patient risk discussions—this may be particularly relevant for women given MESA database findings that women in the highest calcium quintile often had low Framingham risk scores Female‐friendly focus: 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease - PMC nih .
However, BAC has not been formally incorporated as a risk-enhancing factor in cardiovascular prevention guidelines. Multivariable analyses have shown BAC remains an independent predictor of outcomes even when accounting for traditional cardiovascular risk factors, though further research is needed to determine the extent of risk reclassification benefit Breast Arterial Calcification as a Cardiovascular Risk Factor: Time to “Bust” It Out - PMC nih .
Radiologist concerns about AI-related liability represent a significant barrier to adoption. A 2025 Future Health Index survey found 66% of radiologists are concerned about personal liability when AI errors occurFive Reasons Why Radiology AI Has a Trust Problem - Rad AIradai . Compounding this, 80% of health systems have no or limited governance processes in place for AI use despite most having pilots underwayFive Reasons Why Radiology AI Has a Trust Problem - Rad AIradai .
A study published in NEJM AI demonstrated empirically how potential jurors react to AI involvement in malpractice casesUse of AI complicates legal liabilities for radiologists, study finds | The Warren Alpert Medical School of Brown Universitybrown . When no AI was described, participants sided with plaintiffs 56% of the time for a missed brain bleed. When AI agreed with the radiologist's false negative, plaintiff support was similar at 50%. However, when AI correctly detected an abnormality the radiologist missed, plaintiff support increased to nearly 75%Use of AI complicates legal liabilities for radiologists, study finds | The Warren Alpert Medical School of Brown Universitybrown . The researchers concluded radiologists face an "AI penalty" when AI detects abnormalities they miss, though presenting AI error rates (false omission rate, false discovery rate) mitigated this effectUse of AI complicates legal liabilities for radiologists, study finds | The Warren Alpert Medical School of Brown Universitybrown +1.
The legal framework for AI-assisted diagnosis remains evolving. In Sampson v. HeartWise Health Systems Corp. (2023), the Supreme Court of Alabama affirmed summary judgment for the developer of a cardiovascular disease prevention program, holding that under the licensing agreement, physicians retained clinical judgment and final decision-making responsibility about diagnosis and treatment[PDF] Liability Risk For AI In Medical Devices Demands Greater Carecrowell . The case underscores the importance of clear agreements establishing protocols for AI use and management in clinical practice[PDF] Liability Risk For AI In Medical Devices Demands Greater Carecrowell .
As AI evolves toward becoming the standard of care, the liability landscape may shift. If AI-integrated devices become standard practice, physicians who do not use appropriate AI tools or disregard their recommendations may incur liability when patients are injuredRecent Developments in Artificial Intelligence and Accompanying Liability Risks | DAICdicardiology . Conversely, physicians following standard-of-care AI recommendations may avoid liability even when recommendations prove incorrect, potentially shifting responsibility to device manufacturersRecent Developments in Artificial Intelligence and Accompanying Liability Risks | DAICdicardiology .
Survey research of primary care providers regarding AI-enabled opportunistic CT screening found that while 74.6% had heard of AI/machine learning, 95.8% had little-to-no familiarity with opportunistic screening and the majority reported little-to-no trust in AIPrimary care provider perspectives on the value of opportunistic CT screening.nih . Key concerns included AI accuracy (74.6%), unknown liability (73.2%), and added costs to patients (91.5%) and providers (77.5%)Primary care provider perspectives on the value of opportunistic CT screening.nih . Notably, 78.9% reported that opportunistic screening applications would require radiologist oversight, and 70.5% felt primary care practices would be unlikely to pay for such servicesPrimary care provider perspectives on the value of opportunistic CT screening.nih .
Integration of AI into clinical workflows requires addressing trust, usability, and governance concerns. Experienced breast radiologists report that understanding algorithms and developing trust takes substantial time and effort—"telling people what to look for is definitely part of the process, getting up to speed really requires you develop a trust for the algorithm just like in any relationship"Introduction to AI Applications in Breast Imagingyoutube . User interface design critically affects adoption: "if you make it really easy to use people will come and use it... if they have to dig for it and log into a separate system and a separate viewer... it may just get ignored"Integrating AI into the Clinical Workflow with Christoph Wald, MD, PhD, MBA, FACRyoutube .
The workflow considerations extend beyond radiology. Simulation modeling of AI-aided same-day diagnostic workups for breast screening found that maintaining existing resources and schedules unchanged may extend imaging center operating hours and increase patient waiting times Integrating AI into Clinical Workflows: A Simulation Study on Implementing AI-aided Same-day Diagnostic Testing Following an Abnormal Screening Mammogram - PMC nih . Alternative approaches involving reserved appointment slots for AI-triggered workups must be balanced against existing diagnostic capacity Integrating AI into Clinical Workflows: A Simulation Study on Implementing AI-aided Same-day Diagnostic Testing Following an Abnormal Screening Mammogram - PMC nih .
Seamless integration of AI systems with existing picture archiving and communication systems (PACS) and electronic health records is critical for effective collaboration and data sharing Challenges in Implementing Artificial Intelligence in Breast Cancer Screening Programs: Systematic Review and Framework for Safe Adoption - PMC nih . Technical considerations include large storage capacity requirements, compatibility with local imaging equipment and protocols, computational power for deep learning models, and IT security requirements regarding cloud versus on-premises processingIntegrating AI into the Clinical Workflow with Christoph Wald, MD, PhD, MBA, FACRyoutube +1.
Platform marketplace approaches offer potential solutions, allowing single contracts and technical platforms with ability to enable multiple algorithms without separate server deploymentsIntegrating AI into the Clinical Workflow with Christoph Wald, MD, PhD, MBA, FACRyoutube . The American College of Radiology has established AI Central to help members navigate the growing commercial landscape of over 150 algorithms, and the ACR AI Lab offers simulation of AI use in clinical practiceIntegrating AI into the Clinical Workflow with Christoph Wald, MD, PhD, MBA, FACRyoutube .
Research examining BAC across racial and ethnic groups found significant variation in prevalence. A study of 1,905 consecutive women found overall BAC prevalence of 29.4%, with significantly higher rates for Hispanic women compared to white women (34.5% vs 24.0%) and lower rates for Asian women compared to white women (7.1% vs 24.0%)Prevalence of breast arterial calcifications in an ethnically ... - PubMednih . Among BAC-positive women aged 65 or younger, Black women had more calcified arteries than white womenPrevalence of breast arterial calcifications in an ethnically ... - PubMednih .
A Kaiser Permanente analysis found BAC was more prevalent among women self-identifying as white or Hispanic/Latina and less common among Black or Asian womenMammograms may provide clues about women’s risk for cardiovascular disease | American Heart Associationheart . These variations carry important implications given that among Black women over age 20, nearly 59% have cardiovascular disease, with substantially higher prevalence of hypertension (60% vs 40% for non-Hispanic white women), diabetes, physical inactivity, and overweight/obesityWhy Black women are at higher risk of heart disease | 20-Minute Health Talkyoutube .
BAC screening may offer equity advantages by reaching populations with limited healthcare engagement. Researchers in Australia developing mammography-based cardiovascular AI noted: "We hope this technology will one day provide greater, and more equitable access to screening in rural areas, as many women already benefit from mobile mammography units free of charge"New AI algorithm uses mammograms to accurately predict cardiovascular risk in women | The George Institute for Global Healthgeorgeinstitute . The model was designed and validated using mammograms from over 49,000 women in metropolitan and rural Victoria linked to hospital and death records, performing comparably to traditional models requiring multiple clinical data pointsNew AI algorithm uses mammograms to accurately predict cardiovascular risk in women | The George Institute for Global Healthgeorgeinstitute .
A critical gap remains in prospective evidence demonstrating that BAC-triggered cardiovascular interventions reduce clinical outcomes. The Mount Sinai BAC Information Sharing Trial (NCT04983875), recruiting patients since September 2021 with results expected March 2027, represents the first randomized study comparing BAC notification with standard mammography lettersMammography and Breast Arterial Calcification: an Information-Sharing Trial | Mount Sinai - New Yorkmountsinai . The trial randomizes 1,888 patients with BAC into notification versus delayed notification groups, measuring effects on healthcare choices and lifestyleHow a mammogram may help identify heart diseasenbcnews .
Researchers at Emory are planning a clinical trial to test integration steps including AI tool workflow integration and patient/clinician notification guidelinesAI can predict risk of serious heart disease from mammogramsescardio . Until such outcome data emerge, the transformation remains theoretically compelling but empirically incomplete.
Formal health economic evaluation specifically modeling AI-based BAC detection on mammograms for cardiovascular risk stratification—including incremental cost-effectiveness ratios and quality-adjusted life year calculations in developed healthcare systems—remains lacking. While general opportunistic screening economics have been evaluated (cost per diagnosis of $6.82 in public sector settings for cardiovascular conditions in Sri Lanka)Cost-Effectiveness and Distributional Impact of Opportunistic Screening for People at High-Risk of Cardiovascular Disease in Sri Lanka: A Modelling Study | Global Heartglobalheartjournal , analogous modeling for mammography-integrated cardiovascular screening in US or European contexts would be essential for evidence-based policy development.
The absence of standardized quantitative reporting methods limits ability to stratify risk within BAC-positive populations A Review of Artificial Intelligence Models for Detecting Breast Arterial Calcification on Mammograms and Their Clinical Implications - PMC nih . Clear guidance is needed to help women and clinicians interpret BAC findings and respond effectively, including how to tailor approaches for younger versus older women and different patient subsets Breast Arterial Calcification as a Cardiovascular Risk Factor: Time to “Bust” It Out - PMC nih . Achieving this requires purposeful investigation and coordinated efforts to build evidence-based care pathways—without such intentional efforts, clinical implementation will remain fragmented Breast Arterial Calcification as a Cardiovascular Risk Factor: Time to “Bust” It Out - PMC nih .
The transformation of preventive cardiology through mammography-integrated cardiovascular screening represents a genuine opportunity with substantial remaining barriers. The scientific evidence linking BAC to cardiovascular outcomes is robust and growing, with clear dose-response relationships and prognostic value independent of traditional risk factors. FDA regulatory pathways have been navigated successfully for initial BAC detection tools, establishing precedent for market authorization. The scale of potential impact—reaching tens of millions of women through existing screening infrastructure—is substantial.
However, the transformation remains incomplete. Professional society guidelines have not codified BAC reporting standards. Reimbursement pathways specific to mammography-based cardiovascular screening do not exist. Outcome data demonstrating that BAC-triggered interventions reduce cardiovascular events remain pending. Medical-legal frameworks for AI-assisted incidental findings continue evolving. Workflow integration challenges persist in both radiology departments and care coordination pathways.
The realistic assessment suggests a staged transformation: initial clinical adoption by innovative practices and health systems; accumulation of real-world evidence and outcome data; evolution of professional guidelines toward standardized reporting; development of reimbursement codes and coverage policies; and ultimately population-scale implementation. The technology and clinical rationale are available today—translating them into transformed practice requires the slower work of evidence generation, guideline development, and healthcare system adaptation.